Kendra L. Sweet, MD, Moffitt Cancer Center and principal investigator of the SWOG S1712 clinical trial (IMAGE)
Caption
Kendra L. Sweet, MD, a SWOG investigator at Moffitt Cancer Center, reports results of the SWOG S1712 clinical trial at the ESH-iCMLf John Goldman Conference on CML in Prague, September 27th. The phase 2 trial found that adding ruxolitinib to standard treatment with tyrosine kinase inhibitors for chronic-phase chronic myeloid leukemia (CML) increases the percentage of patients who see a deep molecular response to treatment, a response that may allow them to safely discontinue treatment.
Credit
Moffitt Cancer Center
Usage Restrictions
Credit must be given to the creator. Adaptations must be shared under the same terms.
License
CC BY-SA